CA
CMPX icon

CoreCap Advisors’s Compass Therapeutics CMPX Stock Holding History

CoreCap Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-2,664
Closed -$5.06K – 2859
2025
Q1 		$5.06K Buy
2,664
+364
+16% +$968 ﹤0.01% 2091
2024
Q4 		$3.33K Buy
+2,300
New +$3.82K ﹤0.01% 2082

Other funds holding CMPX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CoreCap Advisors's CMPX Position: Q2 2025 in Review

CoreCap Advisors sold out of Compass Therapeutics (CMPX) in Q2 2025, closing a stake of 2,664 shares — an estimated $5.06K sold.

CoreCap Advisors first reported a position in CMPX in Q4 2024 and held it in 2 quarters. The position peaked at $5.06K in Q1 2025. 103 funds tracked by Wall St. Rank hold CMPX as of Q2 2025.

  • CoreCap Advisors reported no remaining Compass Therapeutics position as of Q2 2025 after selling out during the quarter.
  • CoreCap Advisors sold 2,664 Compass Therapeutics shares in Q2 2025, an estimated $5.06K.
  • CoreCap Advisors first reported a position in Compass Therapeutics in Q4 2024 and held it in 2 quarters.
  • CoreCap Advisors's Compass Therapeutics position peaked at $5.06K in Q1 2025.
  • 103 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2025.

Based on CoreCap Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.